RNS and down it goes23 Jul 2018 15:03
SalvaRx (LON: SALV), a biotechnology company focused on immunotherapy for cancer, announces that its 57% owned subsidiary, iOx Therapeutics Limited ("iOx"), has experienced a significant delay in manufacturing its lead drug candidate IMM60.
Due to quality failures in the manufacturing process that led to a batch failure, iOx is revising its timeline to dosing its first human in clinical trials. The company is confident that its process is robust and that it will move the programme forward in due course. Release of the product required for the initiation of human dosing is now likely to be in late 2019.